Proniras Corporation

About Proniras Corporation

Proniras Corporation is a clinical-stage biotechnology company dedicated to developing novel small-molecule therapeutics for the treatment of substance use and specialty central nervous system (CNS) disorders.

Products & Services

Development Programs:Focused on novel small-molecule therapeutics for substance use and CNS disorders, as detailed in their pipeline and clinical trials.

Tezampanel:A treatment under development for seizure disorders, supported by Accelerator Life Science Partners.

Specialties

Small-molecule therapeutics Substance use disorders Central nervous system (CNS) disorders Opiate withdrawal treatment Seizure disorders

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 4650000 MR: - FA: $4.65 million FAN: 4650000	D: 2024-02-01 FD: 2024-02-01	4 investors

Series B Latest

2024-02-01

$4.7M

4 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

T

Thong Q. Le

President and Chief Executive Officer

L

Lindsay Rayle

Vice President of Finance

C

Christopher Toombs

Co-Founder and Chief Scientific Officer

A

Andrew Chambers

Addiction Psychiatry

G

Greg Coulter

Drug Substance/Drug Product

G

Gregory Dietsch

Toxicology and Pharmacokinetics

View 9 more team members with Pro

Unlock Full Team Directory

Recent News